MX2020003095A - Arni variante. - Google Patents
Arni variante.Info
- Publication number
- MX2020003095A MX2020003095A MX2020003095A MX2020003095A MX2020003095A MX 2020003095 A MX2020003095 A MX 2020003095A MX 2020003095 A MX2020003095 A MX 2020003095A MX 2020003095 A MX2020003095 A MX 2020003095A MX 2020003095 A MX2020003095 A MX 2020003095A
- Authority
- MX
- Mexico
- Prior art keywords
- rnai
- recombinant
- disease
- further provided
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se proporcionan moléculas de ARNi para tratar la enfermedad de Huntington. En la presente se proporcionan adicionalmente casetes de expresión, vectores (por ejemplo, vectores de rAAV, adenovirales recombinantes, lentivirales recombinantes, y HSV recombinantes), células, partículas virales, y composiciones farmacéuticas que contienen el ARNi. Aún en la presente se proporcionan adicionalmente métodos y kits relacionados con el uso del ARNi, por ejemplo, para tratar la enfermedad de Huntington.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762561843P | 2017-09-22 | 2017-09-22 | |
PCT/US2018/052221 WO2019060726A1 (en) | 2017-09-22 | 2018-09-21 | VARIANT OF ARNI |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003095A true MX2020003095A (es) | 2020-10-15 |
Family
ID=64017428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003095A MX2020003095A (es) | 2017-09-22 | 2018-09-21 | Arni variante. |
Country Status (18)
Country | Link |
---|---|
US (2) | US11603529B2 (es) |
EP (1) | EP3684932A1 (es) |
JP (1) | JP7248658B2 (es) |
KR (1) | KR20200056428A (es) |
CN (1) | CN111356763B (es) |
AR (1) | AR113134A1 (es) |
AU (1) | AU2018335410A1 (es) |
BR (1) | BR112020005569A2 (es) |
CA (1) | CA3076191A1 (es) |
CO (1) | CO2020003187A2 (es) |
IL (1) | IL273394A (es) |
MX (1) | MX2020003095A (es) |
PH (1) | PH12020550117A1 (es) |
SG (1) | SG11202002488UA (es) |
TW (1) | TW201923079A (es) |
UY (1) | UY37897A (es) |
WO (1) | WO2019060726A1 (es) |
ZA (1) | ZA202001586B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017010369A (es) | 2015-02-10 | 2017-12-14 | Genzyme Corp | Arni variante. |
EP3458589A4 (en) | 2016-05-18 | 2020-01-01 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | ハンチントン病治療組成物および方法 |
US11603529B2 (en) | 2017-09-22 | 2023-03-14 | Genzyme Corporation | Variant RNAi |
CN112980837B (zh) * | 2019-12-13 | 2023-07-04 | 深圳艾码生物科技有限公司 | 一种抑制HTT基因表达的siRNA及其前体和应用 |
CN115141848A (zh) * | 2021-03-30 | 2022-10-04 | 南京大学 | 一种用于治疗亨廷顿病的rna递送系统 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU722624B2 (en) | 1996-09-06 | 2000-08-10 | Trustees Of The University Of Pennsylvania, The | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
AU2001269723B9 (en) | 2000-06-01 | 2006-11-16 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
CA2406745C (en) | 2001-11-13 | 2006-01-10 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
JP2004101787A (ja) | 2002-09-09 | 2004-04-02 | Fuji Xerox Co Ltd | 画像形成装置及び現像装置 |
CA2881743A1 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
CA2596588C (en) * | 2005-01-31 | 2017-06-27 | University Of Iowa Research Foundation | Nucleic acid silencing of huntington's disease gene |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
US8173614B2 (en) * | 2007-01-03 | 2012-05-08 | Medtronic, Inc. | Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof |
US8258286B2 (en) | 2007-04-26 | 2012-09-04 | University Of Iowa Research Foundation | Reduction of off-target RNA interference toxicity |
EP2152874A2 (en) | 2007-04-26 | 2010-02-17 | University of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
WO2009098196A2 (en) | 2008-02-04 | 2009-08-13 | Biofocus Dpi B.V. | Molecular targets and compounds, methods to identify the same, useful in the treatment of neurodegenerative diseases. |
EP2250183A4 (en) | 2008-02-14 | 2012-07-25 | Michael Paul Marie Gantier | SMALL IMMUNOSTIMULATORY RNAI MOLECULES |
FR2929292A1 (fr) * | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
WO2011034811A1 (en) | 2009-09-17 | 2011-03-24 | Sigma-Aldrich Co. | Short rna mimetics |
CA3066596A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
WO2012112832A1 (en) | 2011-02-17 | 2012-08-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
BR112014021104B1 (pt) * | 2012-02-29 | 2023-03-28 | Sangamo Biosciences, Inc | Proteína de fusão de ocorrência não natural compreendendo um domínio de ligação de dna de dedo de zinco manipulado que se liga a um gene htt, seu uso, método in vitro de modificação da expressão de um gene htt em uma célula, e método de geração de um sistema modelo para o estudo da doença de huntington |
CN103224556B (zh) * | 2013-01-31 | 2015-04-15 | 清华大学 | 亨廷顿舞蹈症的靶位蛋白质及其编码基因和应用 |
US9550989B2 (en) | 2013-10-03 | 2017-01-24 | Washington University | Rational design of microRNA-siRNA chimeras for multi-functional target suppression |
NZ719477A (en) * | 2013-11-11 | 2022-05-27 | Sangamo Therapeutics Inc | Methods and compositions for treating huntington’s disease |
FI3628334T3 (fi) * | 2014-03-21 | 2023-09-15 | Genzyme Corp | Geenihoito verkkokalvon pigmenttirappeuma |
CN114231563A (zh) | 2014-05-02 | 2022-03-25 | 建新公司 | 用于视网膜及cns基因疗法的aav载体 |
CN107075514A (zh) * | 2014-05-20 | 2017-08-18 | 衣阿华大学研究基金会 | 亨廷顿氏病的治疗化合物 |
JP6839094B2 (ja) * | 2014-12-24 | 2021-03-03 | ユニクア・アイピー・ベーフェー | RNAiで誘発されるハンチンチン遺伝子抑制 |
MX2017010369A (es) | 2015-02-10 | 2017-12-14 | Genzyme Corp | Arni variante. |
EP3458589A4 (en) * | 2016-05-18 | 2020-01-01 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
US11603529B2 (en) | 2017-09-22 | 2023-03-14 | Genzyme Corporation | Variant RNAi |
AR114540A1 (es) * | 2018-08-03 | 2020-09-16 | Genzyme Corp | VARIANTE DE ARNi CONTRA a-SINUCLEÍNA |
-
2018
- 2018-09-21 US US16/649,042 patent/US11603529B2/en active Active
- 2018-09-21 EP EP18793503.6A patent/EP3684932A1/en active Pending
- 2018-09-21 UY UY0001037897A patent/UY37897A/es not_active Application Discontinuation
- 2018-09-21 WO PCT/US2018/052221 patent/WO2019060726A1/en unknown
- 2018-09-21 SG SG11202002488UA patent/SG11202002488UA/en unknown
- 2018-09-21 CN CN201880073881.6A patent/CN111356763B/zh active Active
- 2018-09-21 JP JP2020516666A patent/JP7248658B2/ja active Active
- 2018-09-21 KR KR1020207011227A patent/KR20200056428A/ko active IP Right Grant
- 2018-09-21 AR ARP180102723A patent/AR113134A1/es unknown
- 2018-09-21 BR BR112020005569-7A patent/BR112020005569A2/pt unknown
- 2018-09-21 AU AU2018335410A patent/AU2018335410A1/en active Pending
- 2018-09-21 CA CA3076191A patent/CA3076191A1/en active Pending
- 2018-09-21 MX MX2020003095A patent/MX2020003095A/es unknown
- 2018-09-25 TW TW107133661A patent/TW201923079A/zh unknown
-
2020
- 2020-03-13 ZA ZA2020/01586A patent/ZA202001586B/en unknown
- 2020-03-16 PH PH12020550117A patent/PH12020550117A1/en unknown
- 2020-03-18 CO CONC2020/0003187A patent/CO2020003187A2/es unknown
- 2020-03-18 IL IL273394A patent/IL273394A/en unknown
-
2023
- 2023-02-15 US US18/169,779 patent/US20230392149A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111356763B (zh) | 2024-03-12 |
CO2020003187A2 (es) | 2020-04-13 |
US20230392149A1 (en) | 2023-12-07 |
TW201923079A (zh) | 2019-06-16 |
RU2020114229A (ru) | 2021-10-22 |
JP2020535803A (ja) | 2020-12-10 |
CN111356763A (zh) | 2020-06-30 |
AU2018335410A1 (en) | 2020-05-07 |
KR20200056428A (ko) | 2020-05-22 |
SG11202002488UA (en) | 2020-04-29 |
RU2020114229A3 (es) | 2022-02-01 |
PH12020550117A1 (en) | 2020-12-07 |
AR113134A1 (es) | 2020-01-29 |
WO2019060726A1 (en) | 2019-03-28 |
CA3076191A1 (en) | 2019-03-28 |
BR112020005569A2 (pt) | 2020-10-06 |
ZA202001586B (en) | 2024-01-31 |
UY37897A (es) | 2019-04-30 |
JP7248658B2 (ja) | 2023-03-29 |
IL273394A (en) | 2020-05-31 |
EP3684932A1 (en) | 2020-07-29 |
US11603529B2 (en) | 2023-03-14 |
US20200216848A1 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013005A (es) | Arni variante. | |
PH12020550117A1 (en) | Variant rnai | |
MX2019013172A (es) | Composiciones y metodos para tratar la enfermedad de huntington. | |
SG10201901482XA (en) | Oncolytic adenovirus encoding a b7 protein | |
MX2020012028A (es) | Metodos y composiciones para tratar el cancer. | |
BR112017005892A2 (pt) | variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma | |
NZ761655A (en) | Cellular models of and therapies for ocular diseases | |
WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
MX2019013151A (es) | Composiciones y metodos para expresar otoferlina. | |
BR112017017867A2 (pt) | métodos e composições para tratamento de doenças oculares genéticas | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
MX2017015666A (es) | Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla). | |
BR112016012968A2 (pt) | Métodos e composições para o tratamento de condições associadas com o envelhecimento | |
EA202190512A1 (ru) | Композиции и способы для производства векторов для генной терапии | |
MX2020005282A (es) | Vector para la produccion de particulas aav. | |
MX2021001395A (es) | Arni variante contra alfa-sinucleína. | |
BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) | |
MX2021005435A (es) | Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2). | |
MX2019008679A (es) | Composiciones para reducir la expresion de sarcolipina y prevenir y tratar la distrofia muscular y la miocardiopatia y metodos de uso. | |
DOP2017000185A (es) | Arni variante | |
MY185846A (en) | Oncolytic adenovirus encoding a b7 protein | |
TH1701004531A (th) | แวเรียนท์RNAi | |
EA201890595A1 (ru) | Онколитический аденовирус, кодирующий белок b7 | |
BR112016021017A2 (pt) | Partículas de raav, composição e uso das mesmas na terapia gênica para retinite pigmentosa |